Keywords
quality of life
How to Cite
Abstract
Psoriasis is a chronic, inflammatory autoimmune disease that primarily affects the skin, causing painful lesions and itching. Psoriasis impacts all aspects of life and significantly reduces the quality of life of patients. The study analyzed the impact of psoriasis on the quality of life of patients, considering physical, psychological, emotional, and social factors associated with the disease. The work also discussed the variety of treatment methods, including pharmacotherapy, phototherapy, biological treatment, and psychological support. Emphasis was placed on the need for an integrated therapeutic approach that considers all dimensions of the patient’s health. The role of lifestyle changes, such as diet and physical activity, in improving the quality of life of patients with psoriasis was also highlighted. A holistic approach to the treatment of psoriasis, which combines various therapeutic strategies and provides comprehensive support to patients, is crucial for improving their quality of life.References
Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol 2017; 76(3): 377–390.
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 2020; 323(19): 1945–1960.
Parisi R, Symmons DPM, Griffiths CEM, et al.; IMPACT project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133(2): 377–385.
Owczarek W, Walecka I, Lesiak A, et al. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Post Dermatol Alergol 2020; 37(6): 821–830.
Parisi R, Iskandar IYK, Kontopantelis E, et al. Global Psoriasis Atlas. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31(2): 205–212.
World Health Organization. Constitution of the World Health Organization. Geneva: WHO; 1946.
Evers AW, Duller P, Jong EM, de, et al. Effectiveness of a multidisciplinary itch coping training programme in adults with atopic dermatitis. Acta Derm Venereol 2009; 89(1): 57–63.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019; 20(6): 1475.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361(5): 496–509.
Chen L, Li J, Zhu W, et al. Skin and gut microbiome in psoriasis: gaining insight into the pathophysiology of it and finding novel therapeutic strategies. Front Microbiol 2020; 11: 589726.
Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers 2016; 2: 16082.
Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303(1): 1–10.
Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386(9997): 983–994.
Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician insights from the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Am J Clin Dermatol 2016; 17(1): 87–97.
Nast A, Gisondi P, Ormerod AD, et al. European S3 guidelines on the systemic treatment of psoriasis vulgaris – update 2015 – short version. J Eur Acad Dermatol Venereol 2015; 29(12): 2277–2294.
Barrea L, Balato N, Di Somma C, et al. Nutrition and psoriasis: is there any association between the severity of the disease and adherence to the Mediterranean diet? J Transl Med 2015; 13: 18.
International Federation of Psoriasis Associations. About IFPA. Dostępny na URL: https://ifpa-pso.com/about-ifpa/ (cyt. 01.07.2024).
National Psoriasis Foundation. About NPF. Dostępny na URL: https://www.psoriasis.org/about-npf (cyt. 01.07.2024).
Psoriasis Association. About Us. Dostępny na URL: https://www. psoriasis-association.org.uk/about-us (cyt. 01.07.2024).
Narodowy Fundusz Zdrowia. Program lekowy B.47 – Leczenie umiarkowanej i ciężkiej postaci łuszczycy plackowatej. Dostępny na URL: https://www.nfz.gov.pl/dla-pacjenta/programy-lekowe- -/b-47/ (cyt. 01.07.2024).
Ogólnopolskie Stowarzyszenie Chorych na Łuszczycę „Psoriasis”. O nas. Dostępny na URL: https://psoriasis.org.pl/o-nas/ (cyt.
Polskie Towarzystwo Dermatologiczne. O nas. Dostępny na URL: https://ptderm.pl/o-nas/ (cyt. 01.07.2024).
Klinika Reumatologii i Immunologii, Gdańsk. Badania kliniczne. Dostępny na URL: https://www.klinika.gda.pl/badania-kliniczne/ (cyt. 01.07.2024).